Variable | Total sample (n = 21) | Phase III slope < 120% (n = 11) | Phase III slope > 120% (n = 10) | P-value between groups |
---|---|---|---|---|
Clinical data | ||||
Age (years) | 54 (42–67.5) | 48 (34–56) | 66.5 (51.5–71.3) | 0.020 |
BMI (kg/m2) | 27.6 (23.9–29.5) | 25 (23.1–29.4) | 28 (26.3–29.8) | 0.16 |
Time from onset of symptoms to diagnosis (months) | 12 (6–24) | 9 (6–18) | 18 (26.3–27) | 0.80 |
Time since diagnosis (months) | 204 (114–252) | 168 (108–240) | 216 (26.3–276) | 0.31 |
CDAI (score) | 13 (9.50–18.5) | 13 (10–19) | 17 (26.3–19.8) | 0.80 |
Serology* | ||||
RF positivity (n, %) | 14 (73.7) | 5 (50) | 9 (100) | 0.021 |
RF (IU/mL) | 128 (5–256) | 23.9 (5–320) | 256 (112–256) | 0.10 |
Anti-CPP positivity (n, %) | 17 (89.5) | 8 (80%) | 9 (100%) | 0.75 |
Anti-CCP (IU/mL) | 126 (42–340) | 104.5 (31.8–347.4) | 175 (51.5–340) | 0.90 |
Lung function | ||||
FVC (% predicted) | 102 (91–105) | 102 (93–105) | 101 (85.3–107) | 0.94 |
FEV1 (% predicted) | 95 (90.5–107.5) | 104 (91–109) | 92.5 (86–102) | 0.17 |
FEV1/FVC (%) | 86 (77.5–88.5) | 86 (85–88) | 80 (74.8–89.5) | 0.36 |
TLC (% predicted) | 92 (85.5–97) | 89 (83–96) | 96.5 (89.8–101.5) | 0.13 |
RV (% predicted) | 78 (52–105) | 68 (54–86) | 99.5 (50–114) | 0.097 |
RV/TLC (%) | 91 (66.5–105) | 76 (63–94) | 104 (85.5–113) | 0.024 |
DLco (% predicted) | 89 (82–100.5) | 89 (85–96) | 89.5 (72.5–106) | 0.86 |
CT | ||||
CT with involvement > 20% (n, %) | 7 (33) | 2 (18.2) | 5 (50) | 0.14 |